Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
Identifieur interne : 000242 ( PubMed/Checkpoint ); précédent : 000241; suivant : 000243Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
Auteurs : Cicely Kerr [Royaume-Uni] ; Emily J. Lloyd [Royaume-Uni] ; Charlotte E. Kosmas [Royaume-Uni] ; Helen T. Smith [Royaume-Uni] ; James A. Cooper [Royaume-Uni] ; Karissa Johnston [Canada] ; Emma Mcintosh [Royaume-Uni] ; Andrew J. Lloyd [Royaume-Uni]Source :
- Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [ 1573-2649 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Choice Behavior, Female, France, Humans, Italy, Levodopa (pharmacokinetics), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Quality of Life (psychology), Spain, Surveys and Questionnaires, United Kingdom.
- MESH :
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease, Quality of Life.
- Adult, Aged, Choice Behavior, Female, France, Humans, Italy, Male, Middle Aged, Spain, Surveys and Questionnaires, United Kingdom.
Abstract
Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP).
DOI: 10.1007/s11136-015-1187-0
PubMed: 26627224
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26627224Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.</title><author><name sortKey="Kerr, Cicely" sort="Kerr, Cicely" uniqKey="Kerr C" first="Cicely" last="Kerr">Cicely Kerr</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Lloyd, Emily J" sort="Lloyd, Emily J" uniqKey="Lloyd E" first="Emily J" last="Lloyd">Emily J. Lloyd</name><affiliation wicri:level="1"><nlm:affiliation>ViiV Healthcare, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ViiV Healthcare, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Kosmas, Charlotte E" sort="Kosmas, Charlotte E" uniqKey="Kosmas C" first="Charlotte E" last="Kosmas">Charlotte E. Kosmas</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Smith, Helen T" sort="Smith, Helen T" uniqKey="Smith H" first="Helen T" last="Smith">Helen T. Smith</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, James A" sort="Cooper, James A" uniqKey="Cooper J" first="James A" last="Cooper">James A. Cooper</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Johnston, Karissa" sort="Johnston, Karissa" uniqKey="Johnston K" first="Karissa" last="Johnston">Karissa Johnston</name><affiliation wicri:level="1"><nlm:affiliation>ICON Epidemiology, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ICON Epidemiology, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Mcintosh, Emma" sort="Mcintosh, Emma" uniqKey="Mcintosh E" first="Emma" last="Mcintosh">Emma Mcintosh</name><affiliation wicri:level="4"><nlm:affiliation>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Lloyd, Andrew J" sort="Lloyd, Andrew J" uniqKey="Lloyd A" first="Andrew J" last="Lloyd">Andrew J. Lloyd</name><affiliation wicri:level="3"><nlm:affiliation>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford, UK. Andrew@bladonassoc.com.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26627224</idno><idno type="pmid">26627224</idno><idno type="doi">10.1007/s11136-015-1187-0</idno><idno type="wicri:Area/PubMed/Corpus">000228</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000228</idno><idno type="wicri:Area/PubMed/Curation">000228</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000228</idno><idno type="wicri:Area/PubMed/Checkpoint">000228</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000228</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.</title><author><name sortKey="Kerr, Cicely" sort="Kerr, Cicely" uniqKey="Kerr C" first="Cicely" last="Kerr">Cicely Kerr</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Lloyd, Emily J" sort="Lloyd, Emily J" uniqKey="Lloyd E" first="Emily J" last="Lloyd">Emily J. Lloyd</name><affiliation wicri:level="1"><nlm:affiliation>ViiV Healthcare, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ViiV Healthcare, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Kosmas, Charlotte E" sort="Kosmas, Charlotte E" uniqKey="Kosmas C" first="Charlotte E" last="Kosmas">Charlotte E. Kosmas</name><affiliation wicri:level="3"><nlm:affiliation>ICON Patient Reported Outcomes, Oxford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>ICON Patient Reported Outcomes, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Smith, Helen T" sort="Smith, Helen T" uniqKey="Smith H" first="Helen T" last="Smith">Helen T. Smith</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Cooper, James A" sort="Cooper, James A" uniqKey="Cooper J" first="James A" last="Cooper">James A. Cooper</name><affiliation wicri:level="1"><nlm:affiliation>GlaxoSmithKline, Brentford, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>GlaxoSmithKline, Brentford</wicri:regionArea><wicri:noRegion>Brentford</wicri:noRegion></affiliation></author><author><name sortKey="Johnston, Karissa" sort="Johnston, Karissa" uniqKey="Johnston K" first="Karissa" last="Johnston">Karissa Johnston</name><affiliation wicri:level="1"><nlm:affiliation>ICON Epidemiology, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ICON Epidemiology, Vancouver</wicri:regionArea><wicri:noRegion>Vancouver</wicri:noRegion></affiliation></author><author><name sortKey="Mcintosh, Emma" sort="Mcintosh, Emma" uniqKey="Mcintosh E" first="Emma" last="Mcintosh">Emma Mcintosh</name><affiliation wicri:level="4"><nlm:affiliation>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Lloyd, Andrew J" sort="Lloyd, Andrew J" uniqKey="Lloyd A" first="Andrew J" last="Lloyd">Andrew J. Lloyd</name><affiliation wicri:level="3"><nlm:affiliation>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford, UK. Andrew@bladonassoc.com.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region></placeName></affiliation></author></analytic><series><title level="j">Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</title><idno type="eISSN">1573-2649</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Choice Behavior</term><term>Female</term><term>France</term><term>Humans</term><term>Italy</term><term>Levodopa (pharmacokinetics)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Quality of Life (psychology)</term><term>Spain</term><term>Surveys and Questionnaires</term><term>United Kingdom</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Choice Behavior</term><term>Female</term><term>France</term><term>Humans</term><term>Italy</term><term>Male</term><term>Middle Aged</term><term>Spain</term><term>Surveys and Questionnaires</term><term>United Kingdom</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26627224</PMID><DateCreated><Year>2016</Year><Month>05</Month><Day>18</Day></DateCreated><DateCompleted><Year>2017</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2649</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>06</Month></PubDate></JournalIssue><Title>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</Title><ISOAbbreviation>Qual Life Res</ISOAbbreviation></Journal><ArticleTitle>Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.</ArticleTitle><Pagination><MedlinePgn>1505-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11136-015-1187-0</ELocationID><Abstract><AbstractText Label="PURPOSE">Long-term levodopa therapy and related fluctuating plasma concentrations are associated with between-dose periods of 'off time' resulting in substantial variation in symptoms and functioning throughout the day in people with Parkinson's (PwP).</AbstractText><AbstractText Label="METHODS">PwP across UK, France, Spain and Italy completed an online survey to explore: the impact of 'off time' on (1) health-related quality of life (HRQL) and (2) on functioning and ability to undertake usual activities; (3) the value of 'off time' relative to other factors associated with Parkinson's through a stated preference discrete choice experiment (SPDCE).</AbstractText><AbstractText Label="RESULTS">In total, 305 PwP completed the online survey. Overall mean HRQL (utility) score was significantly lower for 'off time' (0.37) than for 'on time' (0.60). All attributes within the SPDCE were significant predictors of treatment choice, although increased duration of 'on time' (per hour per day: odds ratio (OR) = 1.40) and predictability of 'off time' to within 30 min (OR = 1.42) were valued most highly.</AbstractText><AbstractText Label="CONCLUSIONS">'On time' and predictability of 'off time' are highly valued by PwP. Due to substantial diurnal variation of Parkinson's symptoms, standard patient-reported outcome (PRO) assessments may not adequately capture the impact of 'off time' on HRQL and participation in daily activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Cicely</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3921-0841</Identifier><AffiliationInfo><Affiliation>ICON Patient Reported Outcomes, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Emily J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>ViiV Healthcare, Brentford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosmas</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>ICON Patient Reported Outcomes, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Helen T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Brentford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Brentford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Karissa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>ICON Epidemiology, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntosh</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Bladon Associates, 3 Kings Meadow, OX2 0DP, Oxford, UK. Andrew@bladonassoc.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Qual Life Res</MedlineTA><NlmUniqueID>9210257</NlmUniqueID><ISSNLinking>0962-9343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="N">Choice Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EQ-5D utility</Keyword><Keyword MajorTopicYN="N">Health-related quality of life</Keyword><Keyword MajorTopicYN="N">Off time</Keyword><Keyword MajorTopicYN="N">Parkinson’s</Keyword><Keyword MajorTopicYN="N">Stated preference discrete choice experiment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26627224</ArticleId><ArticleId IdType="doi">10.1007/s11136-015-1187-0</ArticleId><ArticleId IdType="pii">10.1007/s11136-015-1187-0</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Oxfordshire</li><li>Écosse</li></region><settlement><li>Glasgow</li><li>Oxford</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Kerr, Cicely" sort="Kerr, Cicely" uniqKey="Kerr C" first="Cicely" last="Kerr">Cicely Kerr</name></region><name sortKey="Cooper, James A" sort="Cooper, James A" uniqKey="Cooper J" first="James A" last="Cooper">James A. Cooper</name><name sortKey="Kosmas, Charlotte E" sort="Kosmas, Charlotte E" uniqKey="Kosmas C" first="Charlotte E" last="Kosmas">Charlotte E. Kosmas</name><name sortKey="Lloyd, Andrew J" sort="Lloyd, Andrew J" uniqKey="Lloyd A" first="Andrew J" last="Lloyd">Andrew J. Lloyd</name><name sortKey="Lloyd, Emily J" sort="Lloyd, Emily J" uniqKey="Lloyd E" first="Emily J" last="Lloyd">Emily J. Lloyd</name><name sortKey="Mcintosh, Emma" sort="Mcintosh, Emma" uniqKey="Mcintosh E" first="Emma" last="Mcintosh">Emma Mcintosh</name><name sortKey="Smith, Helen T" sort="Smith, Helen T" uniqKey="Smith H" first="Helen T" last="Smith">Helen T. Smith</name></country><country name="Canada"><noRegion><name sortKey="Johnston, Karissa" sort="Johnston, Karissa" uniqKey="Johnston K" first="Karissa" last="Johnston">Karissa Johnston</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000242 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000242 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26627224
|texte= Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26627224" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |